Plasmodium falciparum parasites are responsible for the major global disease malaria, which results in >2 million deaths each year. With the rise of drug-resistant malarial parasites, novel drug targets and lead compounds are urgently required for the development of new therapeutic strategies. Here, we address this important problem by targeting the malarial neutral aminopeptidases that are involved in the terminal stages of hemoglobin digestion and essential for the provision of amino acids used for parasite growth and development within the erythrocyte. We characterize the structure and substrate specificity of one such aminopeptidase, PfA-M1, a validated drug target. The X-ray crystal structure of PfA-M1 alone and in complex with the generic inhibitor, bestatin, and a phosphinate dipeptide analogue with potent in vitro and in vivo antimalarial activity, hPheP[CH 2]Phe, reveals features within the protease active site that are critical to its function as an aminopeptidase and can be exploited for drug development. These results set the groundwork for the development of antimalarial therapeutics that target the neutral aminopeptidases of the parasite. drug design ͉ malaria ͉ structural biology ͉ protease T here are 300-500 million cases of clinical malaria annually, and 1.4-2.6 million deaths. Malaria is caused by apicomplexan parasites of the genus Plasmodium, with Plasmodium falciparum the most lethal of the 4 species that infect humans. Clinical manifestations begin when parasites enter erythrocytes, and most antimalaria drugs, such as chloroquine, exert their action by preventing the parasite development within these cells (1). As a result of the rapid spread of drug-resistant parasites, there is a constant need to identify and validate new antimalarial targets.
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drug design ͉ malaria ͉ structural biology ͉ protease T here are 300-500 million cases of clinical malaria annually, and 1.4-2.6 million deaths. Malaria is caused by apicomplexan parasites of the genus Plasmodium, with Plasmodium falciparum the most lethal of the 4 species that infect humans. Clinical manifestations begin when parasites enter erythrocytes, and most antimalaria drugs, such as chloroquine, exert their action by preventing the parasite development within these cells (1) . As a result of the rapid spread of drug-resistant parasites, there is a constant need to identify and validate new antimalarial targets.
Intraerythrocytic parasites have limited capacity for de novo amino acid synthesis and rely on degradation of host hemoglobin (Hb) to maintain protein metabolism and synthesis, and an osmotically stable environment within the erythrocyte (1) (2) (3) (4) . Within the erythrocytes, malaria parasites consume as much as 75% of the cellular Hb (1) . Hb is initially degraded by the concerted action of cysteine-, aspartyl-, and metalloendoproteases, and a dipeptidase (cathepsin C) within a digestive vacuole (DV) to di-and tripeptide fragments (5, 6) . These fragments are suggested to be exported to the parasite cytoplasm, where further hydrolysis to release free amino acids takes place [supporting information (SI) Fig. S1 ; see refs. 7 and 8] .
The release of amino acids involves 2 metallo-exopeptidases: an alanyl aminopeptidase, PfA-M1 (9, 10) , and a leucine aminopeptidase, PfA-M17 (7, 11, 12) . We have demonstrated that the aminopeptidase inhibitor bestatin, an antibiotic and natural analogue of the dipeptide Phe-Leu derived from the fungus Streptomyces olivoretticul, prevents P. falciparum malaria growth in culture (13, 14) . More recently, it was shown not only that synthetic phosphinate dipeptide analogues that inhibit metallo-aminopeptidases prevented the growth of wildtype and the chloroquine-resistant parasites in culture but also that one compound, hPheP [CH 2 ]Phe (termed compound 4, Co4), reduced a murine infection of Plasmodium chabaudi chabaudi by 92% compared with controls (15, 16) . Importantly, Co4 was found to cause no toxicity in these in vivo studies (16) . Here, we functionally characterize PfA-M1 and validate it as a target for the inhibitory activity of bestatin and hPheP[CH 2 ]Phe. We also present its 3D structure alone and complexed with both of these inhibitors, which sets the groundwork for the development of a previously undescribed class of antimalarial drugs.
Results and Discussion
Substrate Specificity of the P. falciparum Alanyl Aminopeptidase PfA-M1. The M1 alanyl aminopeptidase gene (MAL13P1.56) (9) , as annotated by PlasmoDB, is present in single copy and located on chromosome 13 of P. falciparum. The gene is 3,257 bp in length and encodes a protein, known as PfA-M1, of 1,085 aa and 126 kDa. The full-length amino acid sequence of PfA-M1 exhibits Ϸ70% sequence similarity with M1 aminopeptidase orthologues of the various rodent malaria species (Plasmodium berghei, P. chabaudi chabaudi, and Plasmodium yoelii); the sequences are most divergent at the large nonconserved Nterminal extension (Ϸ194 aa), which contains 3 asparagine-rich low-complexity regions (LCRs) and a putative transmembrane domain (Fig. S2) .
Using peptide antisera, Florent et al. (9) and Florent and coworkers (10) , detected a 122-kDa PfA-M1 in membrane fractions of malaria parasites. However, this membrane form appeared to be further processed to smaller active soluble forms of 96 and 68 kDa. In our studies, expression of the full-length PfA-M1 was not successful, so a truncated form of the P. falciparum M1 aminopeptidase (residues 195-1085) correlating with the start of the M1 aminopeptidase of Escherichia coli PepN was prepared (17, 18) . The construct lacked the 3 asparaginerich LCRs and the putative transmembrane domain (Fig. S2 ) but was successfully expressed in E. coli and extracted as a soluble functional enzyme. The protein resolved as a major band at Ϸ100 kDa (predicted molecular mass 104.678 kDa) with a minor N-terminally truncated breakdown product of Ϸ55 kDa on reducing SDS/PAGE (Fig. S3) .
The purified recombinant PfA-M1 (rPfA-M1) exhibited a similar retention time on HPLC size analysis as the PfA-M1 in soluble extracts of P. falciparum parasites, both eluting between 80 and 100 kDa (Fig. S3 ). In support of the studies by Florent et al. (9) , and Florent and coworkers (10) , PfA-M1 antisera localized the enzyme to the parasite cytosol (data not shown). Also, P. falciparum D10 parasites transfected with a plasmid (pHTBPfA-M1-cmycB) carrying the truncated PfA-M1 gene expressed and trafficked an Ϸ115-kDa product (Fig. 1A) to the parasite cytosol (Fig. 1B) . These transgenic parasites exhibited a 2.8-fold higher level of PfA-M1 activity compared with D10 wild-type parasites, showing that the transgene product was functionally active within the parasite. Northern blotting experiments showed that the PfA-M1 is expressed at all stages in the development of the malaria parasites in the erythrocyte (Fig. 1C) .
The rPfA-M1 protein displayed a broad specificity for amino acids, demonstrated by its ability to cleave peptide bonds involving hydrophobic, basic, and aromatic amino acids, which is consistent with M1 aminopeptidases of E. coli PepN (17, 18) and Salmonella typhimurium PepN (19 (Table S1 ). However, proline was a poor substrate with k cat /K m a least 1,000-fold less than Leu (Table S1 ), consistent with the catalytic mechanism described by Ito et al. (20) , who suggest that 2 conserved glutamate residues stabilize the reaction intermediate through the formation of hydrogen bonds with the terminal amino group, NH 3 . The presence of a proline in the P1 position may prevent such interactions forming due to the constraints imposed by the cyclized side chain. The rPfA-M1 protein did not cleave after the acidic amino acids Glu and Asp, which is consistent with our suggestion that another enzyme, a cytosolic M18 aspartyl aminopeptidase, is responsible for the specific removal of these residues from peptides (21) .
The efficient cleavage of the amino acid Arg is of particular interest, because this amino acid is not cleaved by the other major malaria aminopeptidase, PfA-M17 (12) . This observation facilitated the development of a specific assay for measuring PfA-M1 in malaria extracts. Thus, by using Arg as a substrate, we showed that rPfA-M1 and native PfA-M1 activity within soluble extracts of malaria parasites exhibited optimal activity at pH 7.0, with Ͻ20% activity below pH 6.0, which is consistent with a cytosolic function for the enzyme (Fig. 1D) (12) . Also, both rPfA-M1 and native PfA-M1 activity depends on a divalent metal ion as metal chelators (1 mM EDTA or o-phenanthroline) were found to inhibit their activity. Collectively, the above data demonstrate that despite lacking the N-terminal domain, rPfA-M1 exhibits physicobiochemical characteristics identical to those of the native soluble malaria PfA-M1 enzyme.
X-Ray Crystal Structure of rPfA-M1 Confirms Bacterial Aminopeptidase Fold. Outside malaria, PfA-M1 shows closest identity (Ϸ35%) to the bacterial M1 aminopeptidases, which do not contain the extended N-terminal domain. We determined the X-ray crystal structure rPfA-M1 to 2.1 Å (Table S2 ). The structure confirmed that rPfA-M1 adopts the bacterial aminopeptidase N-fold (20, 22, 23) , and comprises 26 ␣-helices and 7 ␤-sheets divided into 4 domains ( Fig. 2A) . The catalytic domain II (residues 392-649) adopts a thermolysin-like fold and contains the active site, incorporating the zinc-binding motif H 496 EYFHX 17 KE 519 and the well-conserved G 490 AMEN motif involved in substrate recognition (20, 22, 23) . The catalytic zinc ion is coordinated by N2 atoms of His 496 and His 500 , the carboxyl O atom of Glu 519 , and a water molecule that acts as the nucleophile that attacks the carbonyl carbon of the substrate (20) . This water molecule forms a slightly longer metallo-bond with the zinc ion and is also coordinated by Glu 497 and Glu 463 . It is not clear what the catalytic base of the reaction is, but the structure suggests that it may be the Glu 497 residue.
Inspection of the molecular surface of PfA-M1 reveals 2 openings to the active site cavity. The first opening (N-terminal channel) comprises a shallow 8-Å-long groove at the junction of domains I and IV (Fig. 2B) . The second and larger opening (C-terminal channel) is formed by the C-terminal domain IV, which comprises 8 pairs of ␣-helices arranged in 2 layers to form a cone-shaped superhelical structure. This domain interacts with the catalytic domain II and contains an Ϸ30-Å-long channel leading toward the active site ( Fig. 2C) . At the entrance, a helix (␣14) with a 90°bend confines the pore size to Ϸ13-Å diameter. More recently, a new class of metallo-aminopeptidase inhibitors, phosphinate dipeptide analogues, were designed by using a computer-aided approach by Grembecka et al. (15) ; 1 of these hPheP[CH 2 ]Phe, Co4, exhibited more potent inhibition of rPfA-M1 (K i ϭ 79 nM) than bestatin. Both bestatin and Co4 had similar killing activity against malaria parasites in culture; IC 50 bestatin range 8-14 M and Co4 is 24-62 M (Fig. 3) . However, bestatin only showed low-level (33%) antimalarial activity in murine (P. c. chabaudi) models, whereas Co4 was much more potent and reduced infection by 92% compared with controls (16) .
To elucidate the mechanism by which bestatin and Co4 bound to 
Fig. 3.
The inhibitory effect of the aminopeptidase inhibitor bestatin (squares), and Co4 (triangles) on P. falciparum clone 3D7 growth in culture compared with parasites grown in the absence of inhibitor (circles). Data are presented as mean Ϯ SD of 3 independent, triplicate experiments. Parasites grown in the presence of bestatin or Co4 for 24 h exhibit cellular damage and stunted development compared with control parasites grown in the absence of drug (Inset).
the active site of rPfA-M1, we determined the X-ray crystal structure of rPfA-M1 complexed to each inhibitor to 1.65 and 2.0 Å, respectively ( Table S2 ). Given that the active site of the enzyme is buried in the middle of the protein, we were particularly interested in understanding whether conformational change is required for substrate/inhibitor entry. Interestingly, comparison of the unbound and ligand-bound structures revealed that the enzyme does not undergo any global conformational rearrangements on binding either inhibitor [rmsd of 0.14 (bestatin) and 0.16 Å (Co4) Ͼ890 C␣ atoms]. The omit electron density of ligands within the active site was well defined (Fig. 4) , and the dipeptide analogues slot neatly into the large catalytic cavity without causing any major alterations to active site residues.
In E. coli aminopeptidase N protein Met 454 , positioned immediately preceding the GAMEN exopeptidase motif, is postulated to function as a cushion to accept substrates (20) , altering the size of the active site pocket. This residue is conserved in bacterial aminopeptidases; however, the equivalent position (469) in eukaryote M1 aminopeptidases is commonly a smaller valine or alanine residue. We noted no movement of the rPfA-M1 Val 469 residue to accommodate either the bestatin or Co4 molecule. Indeed, only 2 residues showed significant movement after ligand binding, the Glu 526 side chain that moves away from the active site, removing what would otherwise form a close contact with P1Ј position of either inhibitor (Leu moiety of bestatin or the Phe ring of Co4). However, in the unbound form of rPfA-M1, the Met 1034 residue adopts 2 alternative conformations in the ligand-bound structures, this side chain adopts a single conformation and forms packing interactions with the inhibitor moieties (P1 position).
The lack of any large scale conformational changes in the bound structure suggests that it is unlikely a conformational change is required for active site access. Indeed, initial attempts to obtain data from a ligand-bound complex involved soaking the inhibitor into rPfA-M1 crystals. This procedure caused no deterioration of crystal quality (however, it did result in variable occupancy of the active site, hence cocrystallization was used), also indicating that it is unlikely that large-scale rearrangements of the protein molecules are required for substrate/inhibitor binding. Therefore, we suggest that the active site of this monomeric aminopeptidase is buried, substrate access is achieved by means of the C-terminal domain vortex, and that control of substrate hydrolysis can be achieved, and depends on, the size of this channel.
Both inhibitors primarily interact with the enzyme through a pentahedral coordination with the catalytic zinc ion (Fig. 4) . Aside from bonds with His 496 , His 500 , and Glu 519 , the hydroxyl group (O2) and the carbonyl group (O3) of bestatin and the central phosphoryl O atoms of Co4 are coordinated to the zinc ion (Fig. S4) . Pentahedral zinc coordination, rather than the tetrahedral geometry observed in the unbound structure, is required for the transition state of the enzyme that exists after the nucleophilic attack at the carbonyl carbon of the substrate. The bestatin carbonyl carbon (O3) and the Co4 central phosphoryl O atoms (O3 and O4; Fig. S4 ) also form hydrogen bonds with the side chain of Tyr 580 , stabilizing this reaction intermediate. A cis-peptide (Glu 319 -Ala 320 ) allows the side chain of Glu 319 to extend into the active site, where it forms a hydrogen bond with the N2 atom of bestatin and the amino group (NH 2 ) of Co4 (Fig. 4) . The GAMEN recognition motif residues also contribute hydrogen bonds to ligand binding with the side chain of Glu 463 and main-chain amide of Gly 460 , with both inhibitors (Fig. 4) . Bestatin also forms a hydrogen bond with the mainchain amide of Ala 461 (Table S3 ). When bound, Co4 resides in an extended conformation (Ϸ11 Å from Phe-ring centroids) and has a total contact area of 19.9Å 2 (compared with bestatin total buried surface area of 17.7 Å 2 ). The 2 Phe rings of Co4 form favorable hydrophobic interactions; the Phe ring at P1Ј position (C1-C6, Fig. S4 (Table S3) . However, Co4 is further stabilized by 10 residues contributing to its hydrophobic packing within in the active site core in contrast to bestatin, which has only 7 such interactions with only 1 residue (Thr 492 ), contributing to the stability of the leucyl moiety in the P1Ј position.
Bestatin is a natural analogue of the dipeptide Phe-Leu, but is a much weaker inhibitor of PfA-M1 than Co4. When analyzing the active site contacts of the 2 ligands, a possible distinction between potency to Co4 of bestatin may be due to a lack of contacts made by the leucyl side chain of bestatin, leaving a open hydrophobic cleft that is filled when Co4 is bound. Interestingly, the phosphinate dipeptide hPheP[CH 2 ]Gly (Co2) is a significantly poorer inhibitor than Co4 [having a 13-fold greater K i of 1,030.0 nM than Co4 (hPheP[CH 2 ]Phe)] (16). We suggest that this reduced potency is probably also due to the lack of contacts at the P1Ј position within this large active-site cavity. Because of its high K i , compound hPheP[CH 2 ]Gly does not exhibit antimalarial activity in vitro. However, these data clearly highlight the impact such ligand-binding analysis may have for structure-based drug design in conjunction with biological analysis. The active site of PfA-M1 is buried deep in the structure, providing a solution to the problem of controlling appropriate substrate entry, as well as preventing hydrolysis of unwanted substrates. By comparison with the available bacterial aminopeptidases structures (20, 22, 23) , PfA-M1 can, thus, be considered to adopt a ''closed'' conformation. Interestingly, structural studies on the homologous tricorn-interacting factor 3, F3, reveals this protease undergoes a substantial conformational changes on substrate entry, where domain IV swings away from domain II, exposing the active site. However, for the aminopeptidase N structures available, including PfA-M1, there is no movement of the C-terminal domain noted, even in the presence of inhibitors. We argue that in PfA-M1, the large C-terminal channel functions to permit substrate entry whereby Hb-derived peptides access the buried active site leaving the smaller sized opening for exit of released amino acids. A maximal pore size of 10 Å has been proposed to serve as the entry point in other multimeric proteases structures (22, 25) ; here, we suggest that for such an opening is sufficient to allow access to the buried active site of this monomeric protease.
Given our detailed knowledge of the active site of the PfA-M1 enzyme, high-throughput screening of chemical libraries followed by medicinal chemistry would allow the development of additional lead antimalarial compounds. The static nature of this family of proteases allows the opportunity for a 2-fold approach to rational drug design; discovery of lead compounds that bind to and irreversibly block the active site, and/or compounds that block egress of digestion products by occluding the N-terminal channel, both essentially trapping the molecule in an inactive state.
Conclusions
There is a paucity of new antimalarial drugs entering the development pipeline. Our report of the unique active site structure of PfA-M1, in complex with the antimalarial inhibitors bestatin and Co4, provides the groundwork for the de novo discovery of a previously unrecognized class of antimalarials by using high-throughput chemical screening and medicinal chemistry. Co4 also inhibits the second important neutral aminopeptidase of malaria, PfA-M17 (12, 26) , creating the possibility of developing a 2-target or combination therapy that would be more resilient to the emergence of drug-resistant malaria parasites.
Materials and Methods
Parasite Preparation. P. falciparum clone D10 was cultured as described (27) . For experiments investigating the stage specific expression of PfA-M1, parasites were synchronized by using 2 rounds of sorbitol treatment (28) , and stage specific parasites harvested at ring, trophozoite, and schizont stage. Details of parasites, and methods of immunoblotting, Northern blotting, and transfection can be found in SI Methods.
Enzymatic Analysis. Aminopeptidase activity was determined by measuring the release of the fluorogenic leaving group, 7-amino-4-methyl-coumarin (NHMec) from the fluorogenic peptide substrates (SI Methods).
In Vitro Sensitivity of P. falciparum Malaria Parasites to Aminopeptidase
Inhibitors. The in vitro sensitivity of each parasite population to bestatin, Co4 and Co2 was determined by using [ 3 H]-hypoxanthine incorporation (for further details see SI Methods) (29) . IC50 values were determined by linear interpolation of inhibition curves (SI Methods).
Crystallization, X-Ray Data Collection, Structure Determination, and Refinement. A truncated form of PfA-M1 (residues 195-1085, rPfA-M1) was purified from E. coli (SI Methods); rPfA-M1 at 5 mg/mL in 50 mM Hepes pH 8.5; 300 mM NaCl 5% (vol/vol) glycerol was crystallized in 22% (vol/vol) polyethylene glycol 8000, 10% (vol/vol) glycerol, 0.1 M Tris (pH 8.5), and 0.2 M MgCl2. Crystals of the ligand bound rPfA-M1 complexes were obtained by cocrystallization under similar conditions in the presence of 1 mM ligand. The diffraction data for the unbound, bestatin-bound, and Co4-bound protease were collected to 2.1-, 1.65-, and 2.0-Å resolution, respectively (Table S2) . Crystallographic analysis was performed by using CCP4i (30 -33) . The structure was determined by using the program PHASER (34) (using 2GTQ.pdb as a search probe; see ref. 23) . Refinement was performed by using REFMAC (35) . All model building was done by using COOT (for further crystallization details, see SI Methods) (36) . 
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SI Methods
Parasites and Preparation of Parasite Extract. Plasmodium falciparum clone D10 was cultured as described (1) . For experiments investigating the stage-specific expression of PfA-M1, parasites were synchronized by using 2 rounds of sorbitol treatment (2), and stage-specific parasites were harvested at ring, trophozoite, and schizont stage.
The P. falciparum M1 Alanyl Aminopeptidase Gene. Because of the high AT-richness of genes encoding malarial proteins PfA-M1 was chemically synthesized by GeneArt using codons for optimized gene expression in the yeast Pichia pastoris. Potential N-linked glycosylation sites were removed during gene synthesis by replacing the asparagine of all Asn-Xaa-(Thr/Ser) motifs with glutamine (Gln, Q). However, expression with the codon optimized PfA-M1 in P. pastoris was unsuccessful; therefore, we turned to Escherichia coli as the expression host. In this host, expression of the full-length gene did not result in a functionallyactive enzyme and, therefore, a truncated form of the P. falciparum M1 aminopeptidase (residues 195-1085, rPfA-M1; see Fig. 1 ), which removed N-terminal low-complexity regions and a putative transmembrane region was prepared by PCR amplification using the synthesized gene as a template followed by directional cloning into the bacterial expression vector pTrcHis2B (Invitrogen). The primers used were M1 forward 5Ј-CTGCAGA ACCA A AGATCCAC-3Ј, and M1 reverse 5Ј-GGTACCTCAATGATGATGATGATGATGTGGGCCCA-ACTTGTTTGT-3Ј. Unique PstI and KpnI sites (underlined) were introduced at the 5Ј and 3Ј ends of the amplified product. A C-terminal His-tag was introduced into the M1 reverse primer (italics). The construct housing the truncated PfA-M1 gene was verified by DNA sequencing. The verified construct was then transformed into competent BL21 cells. Expression was carried out as per the supplier's instructions (Invitrogen).
Purification and Molecular Analysis of Recombinant M1 Alanine Aminopeptidase (rPfA-M1). The rPfA-M1 was purified from BL21 cells by using a Ni NTA-agarose column as previously described (3). Native PfA-M1 from soluble extracts of malaria parasites (Ͼ80% trophozoites) was prepared as described previously (3) . Size analysis was performed by (i) SDS/12% PAGE analysis, and (ii) gel-permeation chromatography using a Amersham Pharmacia Biotech Smart System HPLC equipped with a Superdex-200 gel-filtration column. The proteins (40 L containing 10-20 g of protein) were passed through the column at a flow rate of 40 L/min, and fractions were analyzed for aminopeptidolytic activity toward the fluorogenic substrate H-Arg-7-amino-4-methylcoumarin (NHMec) as described below. Separation of the molecular-size standards apoferritin (440 kDa), ␤-amylase (232 kDa), BSA (67 kDa), and carbonic anhydrase (29 kDa) was monitored by A 280 .
Enzymatic Analysis. Aminopeptidase activity was determined by measuring the release of the fluorogenic leaving group, NHMec, from the fluorogenic peptide substrates H-Leu-NHMec, H-AlaNHMec, H-Arg-NHMec, H-Met-NHMec, H-Phe-NHMec, HGly-NHMec, H-Val-NHMec, H-Ile-NHMec H-Glu-NHMec, HAsp-NHMec, and H-Pro-NHMec. Reactions were carried out in 96-well microtiter plates (200 L total volume, 30 min, 37°C) by using a spectrofluorimeter (Bio-Tek KC4), with excitation at 370 nm and emission at 460 nm. Enzyme was first added to 50 mM Tris⅐HCl, pH 8.0, before the addition of 10 M H-Leu-NHMec.
Initial rates were obtained at 37°C over a range of substrate concentrations spanning K m (0.2-500 M), and at fixed enzyme concentrations in 50 mM Tris⅐HCl, pH 8.0. Experiments to characterize the pH optimum and metal dependency of the rPfAM1 were carried out by using various buffers over the pH range 3-10, and in the presence or absence of metal chelators EDTA and o-phenathroline as described (3).
Northern Blotting. Total RNA was extracted and Northern blotting was performed essentially as described by Kyes et al. (4) with the following modifications: 100-L pellet volumes of infected red blood cells were collected from cultures at Ϸ5% parasitemia, lysed, and stored in TRIzol (Invitrogen). Samples were separated on a 1% TBE agarose gel containing 10 mM guanidine thiocyanate (Sigma-Aldrich), soaked in 50 mM NaOH for 30 min, and transferred onto a Hybond Nϩ membrane (Amersham Biosciences).
Blots were probed with a 1,500-bp PCR product amplified from a full-length PfA-M1 pGem clone by using primers PfAM1IntF (TACA ATGGGCT T TAGA ATGTC), and PfAM1IntR (AATTCATCATCTTTTGA). This product was labeled with [␣-32 P]dCTP by random priming by using a Decaprime II kit (Ambion). The probe was hybridized overnight at 40°C in a hybridization buffer containing formamide (Northern Max; Ambion). The filter was washed once at low stringency and twice at high stringency (Northern Max; Ambion), then exposed overnight to Super Rx Medical X-Ray film (Fuji), and developed by using a Kodak X-Omat 3000RA processor (Kodak).
Immunoblotting. Parasite protein fractions were extracted by using 0.03% saponin (Sigma-Aldrich) and prepared as described previously (5) . SDS/PAGE was performed by using 10% acrylamide gels and run on Miniprotein II rigs (BioRad). Equal loading was estimated by using the Bradford method (6), and by staining gels with Coomassie Brilliant Blue (Bio-Rad) with protein proportions visually estimated.
Protein was transferred onto Hybond Cϩ membranes (Amersham Biosciences), which were blocked in 5% skim-milk powder for 1 h at 37°C or overnight at 4°C. Anti-c-myc (Sigma-Aldrich) were used as primary antibody to label transgenic PfA-M1 protein at a 1/3,000 dilution. The secondary antibody was an anti-mouse IgG (Chemicon) used at a dilution of 1/5,000. Blots were incubated with ECL Detection Reagents (Amersham Biosciences), with exposure times ranging from 5 to 10 min. (8) . Each assay was performed in triplicate on at least 2 separate occasions.
Crystallization, X-Ray Data Collection, Structure Determination, and Refinement. Before crystallization, the purified rPfA-M1 enzyme was dialyzed against gel filtration buffer [50 mM Hepes (pH 8.5) 300 mM NaCl, 5% (vol/vol) glycerol] before size-exclusion chromatography using a Superdex S200 10/30 column and concentrated to 5 mg/mL. The crystals were grown by using the hanging drop vapor diffusion method, with 1:1 (vol/vol) ratio of protein to mother liquor (0.5 mL well volume). The crystals appeared overnight in 22% (vol/vol) polyethylene glycol 8000, 10% (vol/vol) glycerol, 0.1 M Tris (pH 8.5), and 0.2 M MgCl 2 and reached full size in 3 days. Crystals of the rPfA-M1-Co4 and rPfA-M1-bestatin complex were obtained by cocrystallization under similar conditions in the presence of the ligand at 1 mM. Crystals were dehydrated against reservoir buffer with 15% (vol/vol) glycerol for 16 h. Crystals were equilibrated for 5 min in reservoir buffer in the presence of 20% (vol/vol) glycerol. Cryoannealing was performed 3 times by blocking the cryostream (100 K) for 5 sec. Cryoannealing substantially improved the diffraction quality observed. Crystal quality was variable and a large number had to be screened.
Data were collected at 100 K by using both in-house and synchrotron radiation. The diffraction data for the ligand-free, Co4-bound, and bestatin-bound protease were collected to 2.1-, 2.0-, and 1.65-Å resolution, respectively. Diffraction images were processed by using MOSFLM (9) and SCALA (10) from the CCP4 suite (11); 5% of each dataset was flagged for calculation of R free (12) with neither a nor a low-resolution cut-off applied to the data. A summary of statistics is provided in Table S2 . Subsequent crystallographic and structural analysis was performed by using the CCP4i interface (13) to the CCP4 suite (11), unless stated otherwise.
Structure solution preceded by using the molecular replacement method and the program PHASER (14) . A search model was constructed from the crystal structure of aminopeptidase N from Neisseria meningitides (PDB ID 2GTQ), the closest structural homolog identified by using the FFAS server (15) . A ''mixed'' model, consisting of conserved side chains (all other non-alanine/glycine residues truncated at C␥ atom), was then created by using the SCRWL server (15) . A single clear peak in both the rotation and translation functions was evident with 1 PfA-M1 monomer placed in the asymmetric unit. Unbiased (F o Ϫ F c ) density in initial electron density maps and initial refinement cycles indicated that this solution was correct. Maximum likelihood refinement using REFMAC (16), incorporating translation, liberation, and screw-rotation displacement (TLS) refinement was carried out, by using a bulk solvent correction (Babinet model with mask). Building was guided by manual inspection of the model and R free . Simulated annealing composite omit maps were generated by using CNS (17) omitting 5% of the model. All model building and structural validation were done by using COOT (18) . Water molecules were added to the model by using ARP/wARP (19) when the R free reached 25%. Solvent molecules were retained only if they had acceptable hydrogen-bonding geometry contacts of 2.5-3.5 Å with protein atoms or with existing solvent, and were in good 2F o Ϫ F c and F o Ϫ F c electron density.
PyMOL was used to produce all structural representations (www.pymol.org). Hydrogen bonds (excluding water-mediated bonds), were calculated by using the CONTACT (11). The atomic coordinates and structure factors have been deposited in the Protein Data Bank, www.rcsb.org (PDB ID codes 3EBG.pdb; 3EBH.pdb; and 3EBI.pdb). S2 . Alignment of Plasmodium species M1 neutral aminopeptidases. Sequence alignment was prepared by using ClustalW and Espript. Identical residues are highlighted in red and conservatively substituted amino acids are written in red. The Plasmodium species are listed on the left. Putative transmembrane domain is boxed in green and asparagine-rich low complexity regions are located within black hashed boxes. The GAMEN substrate recognition motif is boxed in solid black lines and the zinc binding motif is underlined with catalytic residues indicated (asterisk). The first amino acid of the truncated rPfA-M1 that was successfully purified from E. coli is circled. Values in parentheses refer to the highest-resolution shell. 
